<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03428022</url>
  </required_header>
  <id_info>
    <org_study_id>AFLC</org_study_id>
    <nct_id>NCT03428022</nct_id>
  </id_info>
  <brief_title>Apatinib Combined With EGFR-TKI for Advanced Slow-progressed EGFR-TKI Resistant NSCLC</brief_title>
  <acronym>AFLC</acronym>
  <official_title>Apatinib Combined With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Used for the Advanced Slow-progressed Non Small Cell Lung Cancer Patients With EGFR-TKI Resistance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shenzhen People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shenzhen People's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with advanced non-small cell lung cancer (NSCLC) who progress slowly after Epidermal
      Growth Factor Receptor Tyrosine Kinase Inhibitors（EGFR-TKI）resistance will be treated with
      Apatinib and EGFR-TKI. The primary objective is the disease progression free survival of the
      patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with advanced non-small cell lung cancer (NSCLC) who had treated with Epidermal
      Growth Factor Receptor Tyrosine Kinase Inhibitors（EGFR-TKI） and progressed slowly because of
      resistance are underwent with apatinib mesylate and continuous EGFR-TKI. The primary
      objective is the disease progression free survival of the patients. The secondary goals are
      overall survival, duration of response, objective response rates, disease control rates,
      quality of life scores and drug safety. Currently such patients are treated with EGFR-TKI
      continuously, but 3 months later, the disease will be progressed rapidly. This study will
      bring a new treatment that are more effective, less toxic and more convenient for
      NSCLC-patients with EGFR-TKI resistance.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS</measure>
    <time_frame>3 months</time_frame>
    <description>the disease progression free survival of patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>8 months</time_frame>
    <description>overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>6 months</time_frame>
    <description>objective response rates</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>NSCLC</condition>
  <condition>Apatinib</condition>
  <condition>EGFR-TKI</condition>
  <arm_group>
    <arm_group_label>Apatinib combined with EGFR-TKI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Apatinib（Tablet（Tab. ）500millgram（mg）/day（d）） combined with EGFR-TKI（as previously）</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib（Tab. 500mg/d） combined with EGFR-TKI（as previously）</intervention_name>
    <description>Patients with advanced non-small cell lung cancer (NSCLC) who had treated with EGFR-TKI and progressed slowly because of resistance are underwent with apatinib mesylate and continuous EGFR-TKI.</description>
    <arm_group_label>Apatinib combined with EGFR-TKI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathologically confirmed advanced (stage IV) non-squamous, non-small cell lung cancer
             with measurable lesions

          -  Electronics Coordinating Grop（ECOG）score：0-2

          -  Expected survival over 3months

          -  Hemoglobin(HB)≥90 gram(g)/liter(L)；absolute neutrophil
             count(ANC)≥1.5×109/L；platelet(PLT)≥80×109/L；total-bilirubin（T-BIL）&lt;1.5 upper limit of
             normal value（ULN）；alanine aminotransferase（ALT）and aspartate aminotransferase（AST）&lt;2.5
             ULN；Cr≤1.25ULN

        Exclusion Criteria:

          -  Brain metastases, meningococcal meningitis, patients with spinal cord compression with
             evidence of imaging (computed tomography（CT） / magnetic resonance imaging （MRI）, et
             cetera（etc.）);

          -  Uncontrolled hypertension (systolic blood pressure（BP）≥140 millimeter mercury
             column（mmHg） or diastolic BP ≥90 mmHg, despite optimal drug therapy);

          -  Hemorrhoid dysfunction (inernational standard ratio(INR)&gt; 1.5 or prothrombin time
             (PT)&gt; ULN + 4 seconds or activated partial thromboplastin(APTT)&gt; 1.5 ULN) with
             bleeding tendency or undergoing thrombolytic or anticoagulant therapy;

          -  Patients treated with anticoagulants or vitamin K antagonists such as warfarin,
             heparin, or the like;

          -  Patients underwent major surgery or severe traumatic injury, fracture or ulcer in 4
             weeks before study;

          -  Urine routine urine protein ≥ +++, or confirmed 24 hours urinary protein content ≥ 1.0
             g;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>CAO HUA, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shenzhen People's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>CAO HUA, MD</last_name>
    <phone>0086-755-22942406</phone>
    <email>caohua1206@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shenzhen People's Hospital</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <zip>518020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>CAO HUA, MD</last_name>
      <phone>0086-755-22942406</phone>
      <email>caohua1206@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 15, 2018</study_first_submitted>
  <study_first_submitted_qc>February 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 9, 2018</study_first_posted>
  <last_update_submitted>February 4, 2018</last_update_submitted>
  <last_update_submitted_qc>February 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shenzhen People's Hospital</investigator_affiliation>
    <investigator_full_name>Cao，Hua</investigator_full_name>
    <investigator_title>associate chief physician</investigator_title>
  </responsible_party>
  <keyword>Apatinib</keyword>
  <keyword>EGFR-TKI resistance</keyword>
  <keyword>slowly progress</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

